| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714257 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 22 Pages |
Abstract
The results of our exploratory analyses suggest that the improvements seen with tiotropium Respimat as add-on to ICS ± LABA in patients with symptomatic asthma on lung function, exacerbation risk, and symptom control are independent of T2 phenotype.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Thomas B. MD, Eric D. MD, Mark MD, J. Christian MD, Hendrik PhD, Michael MD, Petra MD, Huib A.M. MD,